Bionor Pharma is a leading vaccine company, searching for breakthrough treatments for HIV and other deadly viruses.

Modified Peptide based vaccinesen/Vaccines_+_technology/Platform_technology/The key to kill virusen/Vaccines_+_technology/Platform_technology/Vacc-4x kills virus producing cells.en/Vaccines_+_technology/HIV_vaccine_Vacc-4x/

Latest news

Hide mandatory notifications of trade

Bionor Pharma Announces Completion of Enrollment of Part A of REDUC trial

Scientific .2014

(Oslo 1 April, 2014) Bionor Pharma ASA (OSE: BIONOR) announced today the completion of enrollment of patients for part A of the Phase I/II REDUC study.

Reboost Data Reconfirms 2010 Study

Scientific .2014

Bionor Pharma’s Phase II Therapeutic HIV Vaccine Vacc-4x: Reboost Data Reconfirms 2010 Study

Bionor Pharma Announces Completion of Enrollment of Part A of REDUC trial

Scientific .2014

(Oslo 1 April, 2014) Bionor Pharma ASA (OSE: BIONOR) announced today the completion of enrollment of patients for part A of the Phase I/II REDUC study.

Reboost Data Reconfirms 2010 Study

Scientific .2014

Bionor Pharma’s Phase II Therapeutic HIV Vaccine Vacc-4x: Reboost Data Reconfirms 2010 Study

Go to news section

Featured content